6[1]Stampfer MJ, Colditz GA.Estrogen replacement therapy and coronary heart disease :A quantitative assessment of the epidemiological evidence[J]. Prev Med, 1991,20:47-63
7[2]Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture[J].BM J, 1992,305:1124-1128
8[3]Gambrell RD Jr. Progestogens in estrogen replacement therapy[J]. Clin Obstet Gynecol, 1995,38:890-900
9[4]Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease[J]. N Engl J Med, 1996,335:453-461
10[5]Michaeelsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and risk of hip fracture population based case-control study[J]. BMJ, 1998,316:1858-1863
7Helene BL, Santo L, James NA. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss [J]. Obstet Gynecol, 1999,94:225-231.
8Claudia V, Alexandra W,Andreas E. Clausen, and Andreas Bernkop Schnu rch,Thiolated Polymers: Development and E- valuation of Transdermal Delivery Systems for Progesterone [J].Pharm Res, 2011,18(2) :211 -216.
9Wren BG, McFarland K, Edwards L, et al. Effect of sequen tial transdermal progesterone cream on endometrium bleeding pattern and plasma progesterone and salivary progesterone levels in postmenopausal women[J]. Climacteric, 2000, 3 (3) : 153-154.
10Gambrell R, Don MD. Progesterone skin cream and measure- ments of absorption[J]. Menopause , 2003, 10(1):1 -3.
